Posted by Michael Wonder on 09 Mar 2022
SMC approval welcome news for breast cancer patients
9 March 2022 - Trodelvy is accepted for use in metastatic triple negative breast cancer. patients who have already received two or more systemic therapies
The SMC has accepted Trodelvy (sacituzumab govitecan) for use in Scotland on the NHS, for the treatment of adults with unresectable locally advanced or metastatic triple negative breast cancer.
